Kremens Bernhard, Hero Barbara, Esser Joachim, Weinel Peter, Filger-Brillinger Judith, Fleischhack Gudrun, Graf Norbert, Grüttner Hans-Peter, Niemeyer Charlotte, Schulz Ansgar, Wickmann Lutz, Berthold Frank
Department of Pediatric Hematology-Oncology, Universitäts-Kinderklinik, University of Essen, Hufelandstr. 55, D-45122 Essen, Germany.
Cancer Immunol Immunother. 2002 Apr;51(2):107-10. doi: 10.1007/s00262-001-0259-x. Epub 2002 Feb 1.
Unusual ocular symptoms observed during intravenous treatment with anti-disialoganglioside antibody (Ab) in children suffering from neuroblastoma were analyzed and the results reported. Within the framework of the German Collaborative Neuroblastoma Study NB97, 85 children with high-risk neuroblastoma received anti-GD2 monoclonal antibody ch14.18 intravenously. Side effects were regularly reported to the study center. Ocular symptoms were recorded in clinical detail, duration and development over time. Symptoms of a parasympathetic deficit corresponding to internal ophthalmoplegia, i.e. mydriasis and accommodation deficit, were found in 10 patients. They were uni- or bilateral, began after the termination of Ab infusion and improved or disappeared in all surviving children. They did not reappear or worsen upon repeated Ab infusions. The pathophysiology of these disorders remains poorly understood. It is concluded that during systemic treatment with the anti-GD2 antibody ch14.18, reversible symptoms of parasympathetic denervation of the eye may occur which, however, do not warrant termination of this treatment.
对患有神经母细胞瘤的儿童在静脉注射抗二唾液酸神经节苷脂抗体（Ab）治疗期间观察到的异常眼部症状进行了分析，并报告了结果。在德国神经母细胞瘤协作研究NB97的框架内，85名高危神经母细胞瘤儿童接受了静脉注射抗GD2单克隆抗体ch14.18治疗。副作用定期报告给研究中心。详细记录了眼部症状、持续时间以及随时间的发展情况。在10名患者中发现了与眼内肌麻痹相对应的副交感神经功能障碍症状，即瞳孔散大和调节功能障碍。这些症状为单侧或双侧，在Ab输注结束后开始出现，并且在所有存活儿童中均有所改善或消失。再次输注Ab时，这些症状未再次出现或加重。这些病症的病理生理学仍知之甚少。得出的结论是，在用抗GD2抗体ch14.18进行全身治疗期间，可能会出现眼部副交感神经去神经支配的可逆症状，然而，这些症状并不需要终止这种治疗。
